Is TRT Safe? TRAVERSE, the 2025 FDA Label and the Real Risks

For a man with confirmed low testosterone who is dosed into the normal range and monitored with bloodwork, the best evidence available in 2026 does not show that testosterone replacement therapy raises the risk of heart attack, stroke or cardiovascular death. That is the finding of the TRAVERSE trial, the largest randomized test of the question ever run, and it is the reason the FDA removed the heart-risk boxed warning from every testosterone product in February 2025. It is not the same as saying TRT is risk-free. The same trial saw more atrial fibrillation, more pulmonary embolism, more acute kidney injury and more fractures on testosterone than on placebo, and the FDA replaced the old warning with a new one about blood pressure. Testosterone also thickens the blood, acts on the prostate and switches off sperm production for as long as you take it.

So the accurate answer has two halves. The feared cardiovascular catastrophe did not show up when it was finally tested properly. The ordinary, well-understood risks are still there, and every one of them is caught by the monitoring that a legitimate clinic builds into treatment. Whether TRT is safe for you therefore depends less on the molecule than on three things you control: whether your deficiency is real, whether your dose is physiological, and whether somebody is checking your blood.

This guide walks through the evidence in the order a careful clinician would: what TRAVERSE was, what it found and what it did not, what the FDA changed and why, then each specific risk in turn, with the bloodwork that manages it. It ends with who should not take testosterone, the questions to ask a clinic, and how online care compares with an in-person doctor. The shorter companion piece, is TRT bad for you?, covers the same ground in a few minutes; our complete guide to TRT covers everything else. Nothing here is medical advice.

TRAVERSE is a randomized, double-blind, placebo-controlled trial of testosterone gel in 5,246 men aged 45 to 80 with low testosterone and existing or high-risk cardiovascular disease, designed to find out whether testosterone increases major cardiac events. Its results were published in the New England Journal of Medicine on June 16, 2023. It matters because, until it reported, the cardiovascular question had only ever been studied with observational data and small trials, and those pointed in different directions.

The design is the reason it carries weight. Every participant had two fasting morning testosterone readings below 300 ng/dL and at least one symptom of hypogonadism, so they were men who would qualify for treatment in any clinic. Every one of them also had established cardiovascular disease or a cluster of risk factors, so the trial enrolled exactly the men whose hearts doctors worried about most. Half were randomized to a daily 1.62% testosterone gel titrated to keep levels in the normal range, half to an identical placebo gel, and neither the men nor their doctors knew which. Follow-up ran a median of 33 months. The primary outcome was the first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke, adjudicated by a committee that did not know the treatment assignment.

The trial exists because regulators asked for it. In 2015 the FDA required manufacturers to study cardiovascular safety properly, and a consortium of testosterone makers funded TRAVERSE to meet that requirement. That funding is a legitimate point of scrutiny, discussed below. It does not change the design, which is the gold standard for the question. The full paper is Lincoff et al., NEJM 2023. Our medical review policy explains how we weigh a trial like this against weaker evidence.

The primary endpoint occurred in 7.0% of men on testosterone and 7.3% of men on placebo, a hazard ratio of 0.96 with a 95% confidence interval of 0.78 to 1.17. Testosterone met the trial's prespecified definition of non-inferiority: it did not increase major adverse cardiac events in this high-risk population over roughly three years. The secondary cardiovascular endpoints, which added coronary revascularization and hospitalization for unstable angina, told the same story.

Three things about the result are worth holding onto. It was measured in the highest-risk men, not healthy volunteers, so the reassurance applies to the population that generated the fear in the first place. It was measured against a real placebo with blinded adjudication, so it is not confounded by who chooses to be treated. And the confidence interval rules out a large increase in risk; it does not rule out a small one, which is what a non-inferiority margin means in practice.

What the result does not mean is just as important. A hazard ratio of 0.96 is not a benefit. TRAVERSE did not show that testosterone protects the heart, lowers cardiovascular death or should be used as a cardiovascular treatment. It showed an absence of the specific harm that had been feared. Anyone who reads it as proof that testosterone is heart-healthy is reading more than is there, and anyone who reads it as proof that testosterone is harmless is ignoring the rest of the paper, which is where the next section goes.

Four adverse outcomes were more common on testosterone than on placebo: atrial fibrillation (3.5% versus 2.4%), acute kidney injury (2.3% versus 1.5%), pulmonary embolism (0.9% versus 0.5%) and, in a separate analysis published in the New England Journal of Medicine in January 2024, clinical fractures (3.5% versus 2.5%, a hazard ratio of 1.43). None of these was the primary endpoint, so each carries more statistical uncertainty than the headline result, and the absolute differences are small. They are also biologically plausible, which is why clinicians take them seriously rather than dismissing them as noise.

Atrial fibrillation is an irregular heart rhythm that raises stroke risk and usually needs treatment in its own right. Pulmonary embolism is a clot that has travelled to the lungs, and it fits with testosterone's known effect of raising red cell mass and thickening the blood. Acute kidney injury is a sudden fall in kidney function; the mechanism on testosterone is not established. The fracture finding was unexpected, because testosterone improves bone density, and the authors could not explain it; one hypothesis is that men who felt better became more active and fell more, but that is speculation. The fracture paper is Snyder et al., NEJM 2024.

For a man weighing treatment, these signals translate into questions a clinician should ask before prescribing: any history of arrhythmia, any prior clot, any kidney disease, and any history of osteoporosis or falls. They also explain why the single most important routine blood test on TRT is the hematocrit, which is the early warning for the clotting risk. The signals do not overturn the primary result, but they are the reason the honest summary of TRAVERSE is reassuring rather than triumphant.

The trial was funded by testosterone manufacturers, studied one product (a gel) at doses that kept levels in the low-normal range, had very high discontinuation (more than 60% of men in both arms stopped the study drug early), and ran for a median of under three years. Each limitation narrows what it can prove. Reading the result responsibly means knowing them.

• Funding. A consortium of manufacturers paid for the trial because the FDA required them to. The design, the independent data monitoring and the blinded adjudication are the protections against bias, and they were in place. Patient-safety groups still argued that one industry-funded trial should not erase a decade of caution on its own; that is a position, not a flaw in the data.
• One formulation, modest doses. Participants used a transdermal gel titrated to 350 to 750 ng/dL. The results do not automatically describe weekly injections, which produce higher peaks, or the supraphysiological doses some men use. Mean on-treatment levels in the trial were in fact only modestly above placebo, which is a reason some clinicians think it under-tested the question.
• Discontinuation. When most participants stop the drug, the comparison drifts toward two groups that look alike, which biases a non-inferiority trial toward finding no difference. The investigators addressed this with sensitivity analyses, but it remains the most serious technical criticism.
• Duration. Thirty-three months is long for a trial and short for a therapy men take for decades. TRAVERSE says little about year ten.

None of this makes TRAVERSE weak evidence; it is the strongest evidence that exists. It makes it evidence with edges, and the edges are exactly where continued monitoring and continued research belong.

On February 28, 2025, the FDA announced class-wide labeling changes for all testosterone products: the boxed warning about increased risk of heart attack and stroke was removed, a new warning about increased blood pressure was added, and the existing statement that testosterone is not approved for age-related low testosterone was kept. The agency's announcement is here. The change applied to every approved testosterone product, injectable, gel, patch, pellet and oral alike.

Two parts of the decision are easy to conflate. The removal of the boxed warning rested on TRAVERSE: the trial the agency had required did not find the harm the warning described, so the warning no longer matched the evidence. The addition of the blood-pressure warning rested on a different set of studies: ambulatory blood-pressure monitoring trials that manufacturers had been required to run on several products, which showed that testosterone can raise blood pressure in some men. The FDA moved one concern off the label and another one onto it, in both cases because data had arrived.

What the agency did not do is declare testosterone safe, approve it for ordinary ageing or loosen the requirement that it be prescribed for diagnosed hypogonadism. A label is a list of what is known, and the 2025 label still lists blood clots, polycythemia, prostate effects, fertility suppression and the contraindications that follow. The current prescribing information for the specific product you are offered is the authoritative source, and it is worth reading once.

Between 2013 and 2015 several observational studies reported more cardiovascular events among men prescribed testosterone, prescribing was rising fast, and the FDA responded on March 3, 2015 with a safety communication that cautioned against using testosterone for age-related decline and required a labeling change about possible increased risk of heart attack and stroke. That communication is still online and is worth reading as history.

The studies that triggered it were retrospective analyses of medical records, in some cases of older men with existing heart disease, and they could show association but not cause. Men who are prescribed testosterone differ from men who are not in ways that records do not capture. Other observational studies in the same years found the opposite association. The honest state of knowledge in 2015 was uncertainty, and the regulator's response to uncertainty about a widely used drug was to warn and to demand a definitive trial. That is the system working as designed.

Two parts of the 2015 position have outlasted the warning itself. Testosterone is approved for men with hypogonadism caused by a medical condition, not for the gradual decline that comes with age in the absence of a diagnosis; that limitation is still on every label. And a man whose levels are normal has nothing to replace, so TRT offers him risk without benefit. Those principles did not depend on the cardiovascular question and were not changed by its answer.

For a man with diagnosed low testosterone, dosed into the normal range and monitored, the best randomized evidence does not show an increase in heart attack, stroke or cardiovascular death. The same evidence shows small increases in atrial fibrillation and pulmonary embolism, and testosterone can raise blood pressure. The heart is therefore something to monitor on TRT, not something to fear and not something TRT treats.

In practice that means a clinician should ask about your cardiovascular history before prescribing, check your blood pressure before and during treatment, and check your hematocrit on a schedule. A history of atrial fibrillation, prior clots, poorly controlled hypertension, recent heart attack or stroke, or heart failure does not automatically rule TRT out, since TRAVERSE enrolled exactly such men, but it raises the bar for evaluation and follow-up. A man with none of those and a genuine deficiency is in the group for which the evidence is most reassuring.

It also means that anything which protects the heart still has to come from the usual places: blood pressure control, lipids, glucose, weight, not smoking, and activity. TRT corrects a hormone deficiency. The marketing that presents it as cardiovascular prevention is ahead of the evidence, and the marketing that presents it as a cardiac threat is behind it.

Men with a history of atrial fibrillation, previous deep vein thrombosis or pulmonary embolism, a known clotting disorder, uncontrolled high blood pressure, a hematocrit already near the top of the normal range, heart failure, or a heart attack or stroke within the past six months need individual evaluation before TRT and closer monitoring on it. The Endocrine Society's 2018 guideline lists several of these as reasons to avoid or defer treatment; the TRAVERSE signals add the first three.

The list is not a list of exclusions. It is a list of men for whom the generic answer is not good enough and the plan has to be specific: a cardiologist's view where there is active heart disease, blood-pressure control before starting, a lower starting dose or a formulation that avoids high peaks where hematocrit is a concern, and a tighter schedule of blood counts. For some of these men the right answer will be to treat the other condition first; for a few it will be no.

What it should never be is a questionnaire with an automatic prescription at the end. The value of a licensed clinician in TRT is highest for exactly these men, and the cheapest, fastest route is the wrong one for them. Our provider reviews note how much evaluation each clinic actually does; our clinic versus online guide covers when an in-person specialist is the better choice.

Testosterone raises red blood cell production, which raises hematocrit, which thickens the blood and increases the tendency to clot. TRAVERSE recorded pulmonary embolism in 0.9% of men on testosterone against 0.5% on placebo, and labels have warned about venous thromboembolism since 2014. The risk is real, modest, and the most controllable of all TRT's risks, because its warning sign is a number on a routine blood test.

The mechanism runs through the bone marrow. One of testosterone's normal jobs is to stimulate erythropoiesis, and replacement doses do it too, more so with injections that produce high peaks than with daily gels. Hematocrit, the fraction of blood volume made of red cells, rises over the first months and then plateaus. Past roughly 54% most guidelines advise holding or reducing the dose; the Endocrine Society's threshold is 54%. A man who starts with a hematocrit of 50% has less room than one who starts at 42%, which is why the baseline matters.

The clinical response to a rising count is routine: a lower dose, a switch from large infrequent injections to smaller frequent ones or to a gel, or therapeutic phlebotomy, which is a blood donation prescribed for a reason. Men with a personal or family history of clots or a known thrombophilia should raise it before the first dose. Everyone on TRT should know the warning signs: a swollen, painful, warm leg; sudden shortness of breath; chest pain. Those are emergencies, not messages to the clinic. Our guide to TRT blood work explains the schedule.

It can. The FDA's 2025 blood-pressure warning rests on ambulatory monitoring studies in which testosterone products raised average 24-hour systolic blood pressure by a few millimetres of mercury in some men, an effect that is small for an individual and meaningful across a population because blood pressure is the largest modifiable driver of cardiovascular disease. It is a measurable, manageable effect, not a mystery.

Ambulatory monitoring matters because it captures blood pressure through the day and night rather than at one office visit, and the studies that used it were required by the FDA after the 2015 warning. The size and persistence of the effect varied between products and studies, and some clinicians have argued that longer-term data do not show a sustained rise. The regulator judged the evidence strong enough to warn; the sensible response for a patient is simply to measure.

Measure means a baseline reading before starting, a check at each follow-up, and a home cuff if you already have hypertension. A rise is managed the way blood pressure is always managed, with lifestyle, with medication if needed, and, if it is clearly driven by the testosterone and will not control, by revisiting the dose or the therapy. A clinic that never asks about your blood pressure is missing one of the three numbers the label now tells it to watch.

Erythrocytosis, a hematocrit above the normal range, is the most common laboratory side effect of testosterone therapy, and it is more frequent with injectable testosterone than with gels or patches because injections produce higher peaks. It becomes dangerous when the blood is thick enough to raise clotting risk, which is why guidelines set a threshold, usually 54%, above which the dose is held or reduced.

The effect is physiology doing what it does. Testosterone increases erythropoietin signalling and iron availability, the marrow makes more red cells, and the count climbs over the first three to six months before levelling off. It produces no symptoms you would notice until it causes a problem, which is why it is managed by schedule rather than by how you feel: a complete blood count at baseline, at three months, at six to twelve months, then annually, and again after any dose change.

Three levers bring it down. The first is dose, since the effect is dose-dependent. The second is delivery: moving from a large injection every two weeks to a smaller weekly or twice-weekly injection, or to a daily gel, flattens the peaks that drive the rise. The third is phlebotomy. A man whose clinic has no plan for a hematocrit of 55% is a man whose clinic is not monitoring him. Our injections versus cream versus oral guide covers how the formulations differ on this point.

Current evidence does not show that testosterone therapy causes prostate cancer in men who do not have it. In TRAVERSE's prostate safety analysis, high-grade prostate cancer was rare and no more common on testosterone than on placebo. Testosterone can, however, stimulate an existing prostate cancer, which is why active prostate cancer is a contraindication and why PSA is checked before and during therapy.

The fear came from physiology. Prostate tissue responds to androgens, and lowering testosterone is a treatment for advanced prostate cancer, so for decades the assumption was that raising it must promote the disease. Several decades of data have not borne that out for men with normal prostates, and the modern view is that once prostate androgen receptors are saturated, which happens at fairly low testosterone levels, additional testosterone does not drive further growth. TRAVERSE added the first large randomized data point and it was reassuring.

What remains true is that the prostate has to be watched. Guidelines recommend a baseline PSA, and a digital rectal examination in men over 40 with risk factors, before starting, with PSA rechecked at three to twelve months and then annually. A rise of more than 1.4 ng/mL in the first year, or a PSA above 4 ng/mL, is a reason to stop and refer, not to adjust the dose. Men with a history of treated prostate cancer are a specialist decision. A clinic that starts testosterone without a PSA is skipping a step that exists to protect you.

Yes, modestly. Testosterone commonly produces a small rise in PSA in the first months as the prostate responds to restored hormone levels, and it can worsen lower urinary tract symptoms in some men with benign prostatic hyperplasia, the non-cancerous enlargement that causes a weak stream and night-time urination. Severe untreated urinary symptoms are a reason to defer treatment in most guidelines.

The PSA rise is expected and small, typically a few tenths of a nanogram per millilitre, and it is the reason a baseline reading matters: without one, a clinician cannot tell a normal early rise from a worrying one. The BPH relationship is less consistent; many men notice nothing, some notice their symptoms worsen, and men with a high symptom score before treatment should have that addressed and reassessed first.

Neither effect is a reason to fear TRT. Both are reasons to answer the prostate questions on the intake honestly, to have a baseline PSA drawn, and to tell the clinic if urination changes. The side-effects guide covers what each change usually means.

Testosterone can worsen obstructive sleep apnoea in some men, particularly at higher doses, which is why severe untreated sleep apnoea is listed as a reason to defer therapy in the Endocrine Society guideline and why clinicians ask about snoring, witnessed pauses in breathing and daytime sleepiness before prescribing. The evidence is thinner than for the blood and prostate effects, but the concern is consistent enough to act on.

The relationship runs both ways, which makes it worth a man's attention regardless of TRT. Testosterone is produced largely during sleep, and untreated sleep apnoea lowers it; some men who treat their apnoea with CPAP see their levels rise. A man with loud snoring, pauses in breathing noticed by a partner and unrefreshing sleep should be evaluated for apnoea before anyone concludes that his low testosterone needs replacing, because he may have found a cause.

For a man with diagnosed apnoea on effective treatment, TRT is usually reasonable with monitoring. For a man with symptoms and no diagnosis, the right order is sleep study first. Our guide to what causes low testosterone covers the sleep connection in more detail.

Testosterone from outside the body switches off the pituitary signals (LH and FSH) that tell the testes to make their own testosterone and sperm. Sperm counts fall, often to very low levels, within months of starting, the testicles shrink, and recovery after stopping takes months to a year or more and is not guaranteed. For any man who may want children, this is the most important safety conversation to have before the first dose.

The effect is not a side effect in the usual sense; it is the hormone system working as designed. The brain senses adequate testosterone and stops asking for more, and sperm production depends on the high local testosterone inside the testes that only the testes' own production provides. It is also why TRT is sometimes misused as male contraception and why it fails as one: suppression is incomplete and unpredictable.

The alternatives exist and are prescription decisions. Enclomiphene and clomiphene stimulate the body's own production and preserve fertility; hCG can maintain testicular function alongside TRT; sperm banking before starting is cheap insurance. A clinic that prescribes testosterone to a man in his twenties or thirties without raising this has failed him. Our guides to TRT and fertility and enclomiphene versus TRT cover the options, and the best TRT for fertility page lists the clinics that take them seriously.

Acne and oily skin, fluid retention, breast tenderness, soreness at the injection site, mood swings when levels peak and trough between doses, and, with gels, the risk of transferring testosterone to a partner or child through skin contact. Most are mild, most appear early, and most respond to a change in dose, frequency or formulation. They are a different category from the cardiovascular, blood and prostate risks above, and they are what most men actually experience.

• Skin. Acne and oiliness are common in the first months and usually settle; they are more pronounced at higher levels.
• Fluid. Mild ankle swelling or a few pounds of water weight; more important in men with heart or kidney disease.
• Breast tissue. Tenderness or enlargement from the conversion of some testosterone to estradiol; our TRT and estrogen guide explains why routine estrogen blockers are usually the wrong answer.
• Injection sites. Soreness and occasional lumps, which improve with technique and smaller volumes.
• Mood and energy swings. The signature of large infrequent injections; weekly or twice-weekly dosing smooths them.
• Transfer. Gel on uncovered skin can reach a partner or child and cause virilization; wash hands, cover the site, and let it dry.

Every one of these is a reason to message the clinic, not to stop quietly or to push through. The adjustments are routine. Our dedicated side-effects guide goes through each one.

Correcting a real deficiency often improves mood, energy and motivation, and the TRAVERSE investigators reported modest improvements in depressive symptoms among men who had them at baseline. Levels that run too high, or that swing between injections, can produce irritability, restlessness and anxiety. TRT is not a treatment for depression, and the two conditions overlap enough that a clinician should evaluate each on its own terms.

The positive side is well documented in men with genuine hypogonadism: the flat, low-drive state that low testosterone can cause lifts when the hormone is restored. The negative side is dose and rhythm. Supraphysiological peaks after a large injection can make a man edgy for two days and flat for the next five; the fix is a smaller, more frequent dose, not a stronger one. A man who becomes aggressive or anxious on TRT is usually a man whose levels are too high or too variable.

The boundary matters because the symptoms of depression and of low testosterone look alike, and a man with depression who is prescribed testosterone can lose months waiting for a treatment that was never aimed at his problem. A good intake asks about mood directly. If low mood persists on well-managed TRT with normal levels, that is information pointing somewhere else.

For appropriately selected men who stay monitored, long-term TRT is widely practised and the risks that need managing over years are the same ones that need managing in the first months: hematocrit, blood pressure, PSA and the continued suppression of natural production. The randomized evidence runs to about three years; beyond that, safety rests on monitoring rather than on trial data.

That is an honest limitation rather than a hidden danger. Few therapies for chronic conditions have decade-long randomized trials, and testosterone is not unusual in relying on observational follow-up and routine surveillance for its long-term record. What the observational record shows is consistent with the trial: the problems that arise over years are the known ones, they are detectable by bloodwork, and they are rare in men whose clinics check.

The practical consequence is that long-term TRT is a long-term relationship with a clinic. The quality of that clinic's follow-up at year four matters more than its price in month one. A man who plans to be on testosterone for twenty years should choose on monitoring, access to a clinician and willingness to adjust, and should read our guide to whether you can stop TRT before he starts, so that the exit is understood as well as the entrance.

TRAVERSE enrolled men aged 45 to 80, with a mean age of 63, so its reassurance applies directly to older men with confirmed deficiency. Age also raises the stakes on every monitored risk: prostate disease, cardiovascular disease, atrial fibrillation and falls are all more common after 65, the fracture signal was seen in this population, and the label still says testosterone is not for age-related decline without a diagnosis.

The distinction that governs older men is between hypogonadism and ageing. A 70-year-old with a morning testosterone of 180 ng/dL, low libido, anaemia and loss of muscle has a condition that TRT treats, and the evidence supports treating it with monitoring. A 70-year-old with a level of 320 ng/dL and no symptoms has a number that reflects his age, and treating it exposes him to the risks for no demonstrated benefit. Most men in between need a clinician who will say which group they are in rather than a form that says yes.

For older men who do qualify, the plan should include a baseline PSA and examination, a frank discussion of cardiovascular history, a bone-density conversation if there is any fracture history, and a tighter early schedule of blood counts. Our testosterone levels by age guide covers what a normal number looks like at 70.

A young man with confirmed, symptomatic low testosterone can be treated safely, but the bar is higher, for two reasons: a genuinely low level before 40 usually has a specific cause that deserves finding, and a young man is far more likely to want children, which TRT prevents for as long as he takes it. Fertility-sparing alternatives should be discussed first, not after.

The causes worth finding include pituitary problems such as a prolactin-secreting tumour, prior anabolic steroid use that has suppressed the axis, opioid medication, severe obesity, untreated sleep apnoea, and primary testicular conditions. Several are reversible, and a man who reverses one keeps his own production. The workup that distinguishes them, LH, FSH, prolactin, iron studies and a careful history, is the part of the evaluation that fast online clinics most often skip.

For the young man who does need treatment, the conversation about enclomiphene, hCG and sperm banking belongs before the prescription, and the clinic that does not raise it is the wrong clinic. He should also expect to be on therapy for a very long time, which makes the quality of monitoring the deciding factor. Our guide for beginners covers how to approach that first decision.

Not the molecule but the circumstances: testosterone taken without a diagnosis, at doses above the physiological range, from an unregulated source, by a man with a contraindication, or without the bloodwork that would catch a rising hematocrit or PSA. Every serious harm associated with testosterone is more likely in those conditions and much less likely outside them.

• No diagnosis. A man with normal levels gains nothing and keeps all the risk.
• Supraphysiological doses. Levels pushed far above normal for muscle or performance multiply the clotting, cardiovascular and hormonal harms; that is anabolic steroid use, whatever it is called. Our TRT versus steroids guide draws the line.
• Unregulated product. Underground testosterone can be underdosed, overdosed, contaminated or something else entirely.
• Contraindications ignored. Active prostate or breast cancer, a hematocrit already above range, an untreated clotting disorder.
• No monitoring. The problems that bloodwork catches early are the ones that cause harm late.

Seen this way, safety is mostly in the patient's hands. The man who gets a real diagnosis, uses a licensed clinic, takes a replacement dose and keeps his lab appointments has aligned himself with the conditions under which the evidence is reassuring. The man who buys a vial from a gym contact has recreated the conditions under which it is not.

Because it removes every safeguard at once. There is no test to show the man needs it, no clinician to catch a contraindication or set a dose, no bloodwork to detect thickening blood or a rising PSA, and no assurance that the vial contains what the label says at the strength it claims. The evidence that TRT is reasonably safe is evidence about supervised therapy; none of it transfers to self-sourced testosterone.

Each missing piece maps onto a specific harm. Without a diagnosis, men with normal levels suppress their own production for nothing. Without a dose set by a clinician, levels drift high and hematocrit follows. Without a blood count, the first sign of erythrocytosis can be a clot. Without a PSA, an existing prostate cancer is fed rather than found. Without pharmaceutical quality control, the dose is a guess. And when something goes wrong there is nobody to call.

The irony is that legitimate access has never been easier. Telehealth clinics arrange morning blood draws, licensed clinician review and monitored prescriptions without an office visit, often at prices below the underground market once bloodwork is counted. Our guide to how to get TRT online walks through the proper process; the clinic comparison shows what each one includes.

Monitoring converts each of TRT's risks from something that happens to you into something that is measured, noticed and adjusted before it causes harm. The rising hematocrit behind the clotting risk shows up on a blood count months before any clot. A PSA trend shows up before a prostate problem is symptomatic. Blood pressure is a number on a cuff. Testosterone levels tell the clinician whether the dose is right. It is not an add-on to TRT; it is the thing that makes the evidence apply to you.

The Endocrine Society's schedule is a reasonable template: evaluation at three to six months after starting, then annually, with testosterone level, hematocrit and PSA at each point and blood pressure throughout. The schedule tightens after any dose change and for men with risk factors, and it never stops while therapy continues.

The quality of monitoring is also the clearest way to tell clinics apart, because the drug is the same everywhere. A clinic that establishes a full baseline, retests on schedule, has a clinician who reads the results and adjusts, and makes it easy to reach someone when a reading is off is delivering the therapy TRAVERSE studied. One that prescribes and disappears is delivering the risk without the protection. Our ranking method weights monitoring for exactly this reason.

Before starting: two morning total testosterone readings on separate days, a complete blood count for hematocrit, PSA in men over 40, and usually LH, FSH, estradiol and a metabolic panel to find the cause and establish baselines. During treatment: testosterone, hematocrit and PSA at three to six months and then yearly, with estradiol if symptoms suggest it and blood pressure at every visit.

• Total testosterone, drawn in the morning, confirms the diagnosis and later shows whether the dose has landed in the target range rather than above it.
• Hematocrit is the single most important safety number on therapy, for the clotting reasons above.
• PSA tracks the prostate; the baseline is what makes later values interpretable.
• LH and FSH distinguish a testicular problem from a pituitary one before treatment, which changes the plan.
• Estradiol is checked when there is breast tenderness, fluid retention or mood change, not routinely suppressed.
• Blood pressure, per the 2025 label, at baseline and follow-up.

A clinic that includes these in its price is not padding the bill; it is doing the job. A clinic that charges less by skipping them is charging you later. Our blood-work guide goes through each test and what the numbers mean.

Men with active prostate or breast cancer, a palpable prostate nodule or PSA above 4 ng/mL that has not been evaluated, a hematocrit above the normal range, severe untreated sleep apnoea, uncontrolled heart failure, a heart attack or stroke in the past six months, an untreated clotting disorder, severe untreated urinary symptoms from an enlarged prostate, or a plan to father a child in the near future. And men whose testosterone is normal, for whom there is nothing to replace. This is the Endocrine Society's list, lightly paraphrased; the full guideline is Bhasin et al., 2018.

Most entries are temporary rather than absolute. Apnoea can be treated, blood pressure controlled, a prostate evaluated, a hematocrit investigated, and a man who wants children can choose a fertility-sparing option now and TRT later. The point of the list is sequence: treat or evaluate the other thing first. Only active hormone-sensitive cancer is a hard stop in nearly every case.

None of it is self-assessable, which is the argument for a real intake and a real clinician rather than a checkout flow. The clinics that ask the awkward questions are the ones protecting you.

Ask how the diagnosis will be confirmed, what will be monitored and how often, what happens if your hematocrit or PSA rises, how fertility will be handled, who you can reach if something feels wrong, and what would make the clinic stop or change your treatment. The answers tell you whether you are dealing with a medical service or a sales funnel.

• Will you require two morning testosterone tests before prescribing?
• What is the follow-up lab schedule, and is it included in the price?
• What hematocrit level makes you lower the dose, and what do you do then?
• What is your plan if my PSA rises?
• Will you check my blood pressure, and what if it goes up?
• I may want children: what are my options, and will you discuss enclomiphene or hCG?
• How do I reach a clinician between visits?
• Under what circumstances would you decline to treat me?

A clinic that answers these clearly and without irritation is the kind of clinic the evidence assumes. A clinic that treats them as obstacles is telling you something. Our reviews record how each provider handles them.

Look for required bloodwork before prescribing and on a published schedule afterwards, a named licensed clinician who reviews results and is reachable, monitoring of hematocrit, PSA and blood pressure, honest handling of fertility and contraindications, transparent all-in pricing, and a willingness to say no. Treat the opposite patterns as warnings: prescriptions with minimal testing, no reachable clinician, cutoffs set so high that nearly everyone qualifies, and marketing that sells testosterone like a supplement.

The good news is that the fundamentals are present at most legitimate telehealth clinics, and the differences between them are matters of depth, price and convenience rather than whether they test at all. The bad news is that a minority have built businesses on the opposite model, and they are often the cheapest and loudest.

Our comparison ranks clinics on these criteria, our reviews document each one's intake, labs and follow-up, and our cost guide shows what the all-in price actually buys.

For a man with straightforward hypogonadism, yes, provided the online clinic does the same things a good in-person practice does: morning bloodwork through a partner lab or at-home draw, a licensed clinician who reviews it and takes a history, a physiological dose, and scheduled monitoring. The medium does not determine safety; the standard of care does. Complex cases, active heart disease, prostate concerns and confusing hormonal pictures still benefit from in-person specialist care, and a good online clinic refers them.

A poor in-person clinic that hands out testosterone after one afternoon blood test is less safe than a good online clinic that insists on two morning draws and a three-month follow-up. The question to ask is not whether a clinic is online but whether it tests, evaluates, monitors and can be reached. Many online clinics clear that bar; some brick-and-mortar men's health franchises do not.

Our clinic versus online guide sets out when each is the better choice, and the how to get TRT online guide describes what a proper remote process looks like step by step.

Go to emergency care for chest pain or pressure, sudden shortness of breath, a swollen, painful or warm leg, sudden severe headache, vision change, facial drooping, arm weakness or trouble speaking, or fainting. Contact your clinic promptly for a new high blood-pressure reading, persistent or worsening side effects, marked mood change, breast tenderness or enlargement, changes in urination, or anything that worries you.

The emergency list covers the clot and cardiovascular events that are TRT's rare serious harms, and acting fast on them changes outcomes. The clinic list covers the signals that the dose, the formulation or the monitoring need adjusting. Neither list should make a man anxious about every ache; the point is to know the handful of red flags and to have a clinic that answers when one appears.

A clinic's reachability is therefore a safety feature. When choosing one, find out how you contact a clinician and how quickly they respond, because the moment you need that answer is not the moment to discover there is no one there.

Nobody knows, and anyone who tells you otherwise is guessing. TRAVERSE was a three-year cardiovascular safety trial, not a mortality trial; it found no increase in cardiac events and no decrease either. Observational studies linking low testosterone to earlier death cannot separate the hormone from the illnesses that lower it. There is no good evidence that TRT extends life and no good evidence that it shortens it.

The marketing of testosterone as longevity medicine runs well ahead of that. So does the fear that it is slowly killing its users. For a man with real hypogonadism, TRT is a treatment for the symptoms and consequences of that deficiency, including anaemia, bone loss and loss of muscle, with a cardiovascular profile that the best evidence finds reassuring over the medium term. That is a worthwhile thing. It is not an anti-ageing drug.

The interventions with real evidence for living longer remain the unglamorous ones. A man who wants the benefits of TRT should pursue them for what they are, and our benefits guide keeps the same discipline about what is and is not demonstrated.

Untreated hypogonadism is not risk-free. It is associated with anaemia, loss of bone density and higher fracture risk, loss of muscle and strength, sexual dysfunction, low mood and reduced quality of life. For a man with a confirmed, symptomatic deficiency, the honest comparison is between the monitored risks of treatment and the costs of leaving a real condition alone, not between TRT and nothing.

That framing cuts both ways. It is why guidelines support treating men who meet the diagnostic criteria, and it is why they do not support treating men who do not: a man with normal levels has no untreated condition, so for him the comparison is risk against nothing. The quality of the diagnosis is what decides which comparison applies.

For the man in the first group, properly managed TRT usually comes out ahead; for the man in the second, it cannot. The whole apparatus of morning testing, repeat confirmation and symptom assessment exists to put each man in the right group before anyone writes a prescription.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone for men with symptoms and unequivocally, consistently low morning levels; recommends against it for men with the contraindications listed above and for men whose only finding is a lower level with age; and specifies the monitoring schedule described in this guide. The American Urological Association's 2018 guideline is broadly consistent, with a diagnostic threshold of 300 ng/dL and the same emphasis on repeat testing and surveillance.

Three principles run through both: diagnosis before treatment, selection before prescription and monitoring throughout. Both predate TRAVERSE and both anticipated it by advising that cardiovascular risk be discussed and that men with recent events be deferred. Neither has been overturned by the 2025 label change; if anything, the label now matches them more closely.

For a patient, the guidelines are a benchmark for the clinic in front of him. A clinic whose process resembles them is practising mainstream medicine. One that departs sharply from them, by prescribing on a single reading, skipping PSA, or treating a normal level, is not. Our medical reviewer checks the hub's TRT content against current guidance, as our review policy describes.

Start with whether the deficiency is real; if it is not, the benefit side is empty and the decision is made. If it is, list your individual risk factors, recognise that most of TRT's risks are monitored and manageable, weigh the costs of leaving a genuine deficiency untreated, and match the depth of the clinic to the complexity of your case. Then decide with a clinician, not with a landing page.

• Diagnosis. Two low morning readings and symptoms, or no deal.
• Your risks. Heart history, clots, prostate, blood pressure, fertility goals.
• Their manageability. Hematocrit, PSA and blood pressure are numbers a clinic tracks.
• The cost of waiting. Real for real hypogonadism; zero for a normal level.
• The clinic. More complexity needs more clinical depth, not a lower price.

For many men with genuine, symptomatic deficiency and ordinary health the balance favours treatment. For others it favours fixing weight, sleep or a medication first, or waiting, or not treating. Each of those is a correct answer for someone. The only wrong answer is the one made without the information in this guide.

Properly diagnosed, dosed and monitored, TRT is a reasonably safe treatment for low testosterone. The largest randomized trial found no increase in heart attack, stroke or cardiovascular death; the FDA removed the heart-risk boxed warning in February 2025. The remaining risks are real and specific: thicker blood and clots, a possible rise in blood pressure, effects on the prostate, suppressed fertility, and small signals of atrial fibrillation and fracture that deserve respect. Every one of them is managed by bloodwork, selection and a clinician who pays attention.

What changed in the last three years is the cardiovascular picture, and it changed because the question was finally tested properly. What did not change is that testosterone is a prescription hormone whose safety lives in the process around it. The single largest factor in whether TRT is safe for you is whether you pursue it the right way: a real diagnosis, a legitimate clinic, a replacement dose and the lab appointments kept.

This guide is general information, not medical advice. It reflects the TRAVERSE trial (New England Journal of Medicine, 2023) and its substudies, the FDA's testosterone communications of March 3, 2015 and February 28, 2025, and the Endocrine Society's 2018 guideline. Labels and evidence change; confirm current prescribing information with a clinician or pharmacist. TRT requires blood tests confirming low testosterone and ongoing monitoring; talk to a licensed clinician before starting, changing or stopping it. Compare clinics on these safety fundamentals in our TRT comparison and provider reviews.